Physician profile
Vicky Paul
NPI 1821479817
$331.43
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $33.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $121.27 | 2021 | |
| Avanir Pharmaceuticals, INC. | $80.10 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $33.28 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.67 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.02 | 2021 | |
| Amarin Pharma, INC. | $20.04 | 2021 | |
| Astellas Pharma US INC | $16.15 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.90 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.